Compare LARK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | DTIL |
|---|---|---|
| Founded | 1885 | 2006 |
| Country | United States | United States |
| Employees | 283 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 194.3M |
| IPO Year | 2001 | 2019 |
| Metric | LARK | DTIL |
|---|---|---|
| Price | $26.68 | $7.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 3.2K | ★ 209.6K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.43 | $3.53 |
| 52 Week High | $30.85 | $8.82 |
| Indicator | LARK | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 56.96 |
| Support Level | $27.01 | $4.56 |
| Resistance Level | $28.93 | $7.59 |
| Average True Range (ATR) | 0.64 | 0.45 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 45.69 | 38.69 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).